Exclusive Summary

• Backed by US-FDA GMP certification and an ANDA currently under review, this asset offers scarce First-to-File (FTF) or early-wave generic potential globally.
• Targeting a massive global heart failure population (approx. 64 million), it is a first-in-class sGC stimulator recommended by major US and EU guidelines as a crucial add-on therapy for worsening HFrEF.
• With the originator priced at premium levels, this FDA-standard generic provides exceptional pharmacoeconomic value, making it highly competitive for national tenders and insurance formularies.
• Open for global Distribution partnerships, empowering overseas clients to launch immediately in non-IP-restricted markets or secure early commercialization advantage for Day-1 launch in regulated markets.